Studies related to LDL-C and Ashwagandha

Hypoglycemic, Diuretic And Hypocholesterolemic Effect Of Winter Cherry (Withania Somnifera, Dunal) Root

Effect Decrease
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 12
Gender Both Genders
Body Types Overweight, Average
Notes for this study:
6 persons with Type II diabetes and 6 persons with high cholesterol demonstrated lipid lowering effects, anti-glycemic effects, and a diuretic effect.

Exploratory Study To Evaluate Tolerability, Safety, And Activity Of Ashwagandha (Withania Somnifera) In Healthy Volunteers

Effect Decrease
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 17
Gender Both Genders
Age Range 18-29
Body Types Average
Notes for this study:
In an exploratory toxicological study in otherwise healthy persons, supplementation of a water extract at 750 mg for 10 days followed by 1,000 mg and 1,250 mg for 10 days each (equivalent to 6 g, 8g , and 10 g of the dry root) noted a 9.3% reduction in total cholesterol which was thought to be due to LDL cholesterol (trending to decrease) and a significant increase in strength in the quadricep and back extensor muscles (but not grip) was noted after 30 days despite no exercise.

A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans: A Double-Blind, Randomized, Placebo-Controlled Study
Effect Decrease
Values mg/dl. Placebo: before 119.5 (28.6), after 118.8 (26.9). 125 mg before 122.7 (25.0), after 114.9 (18.3). 250 mg before 118.1 (26.2), after 107.5 (22.7). 500 mg before 134.7 (20.4), after 111.2 (14.0)
Trial Design randomized
Trial Length 16months
Number of Subjects 130
Gender mixed
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 130 participants with an anxiety disorder were assigned to take 125 mg, 250 mg, or 500 mg of ashwagandha extract containing a minimum of 8% withanolide glycosides, 32% oligosaccharides, and a maximum of 2% withaferin A for 60 days. 32 participants dropped out, with more dropouts in the placebo group. While the placebo group saw no notable changes, the ashwaganda groups all saw statistically significant improvements compared with the placebo group in stress/anxiety, fatigue, flushing, perspiration, loss of appetite, headache and muscle pain, feelings of impending doom, palpitations, dry mouth, sleeplessness, forgetfulness, irritability, and inability to concentrate. The 250 mg and 500 mg groups seemed to be somewhat more potent than the 125 mg group for stress/anxiety, fatigue and inability to concentrate. Serum cortisol, CRP and serum VLDL-C, and blood pressure were statistically significantly reduced compared with placebo in all ashwagandha groups, and DHEAS was significantly increased. Fasting blood glucose, total serum cholesterol, serum triglycerides, LDL-C, and HDL-C were improved in the 250 mg and 500 mg groups compared with placebo, and the 500 mg group was significantly lower than the 125 mg group for all but CRP and fasting blood glucose.
Funding issues for this study:
"We would like to thank Natreon Inc. (New Brunswick, New Jersey) for financial support of this study. " "Dr. Auddy is an employee of Natreon Inc., which is the patent holder of Withania somnifera extract sold under the trade names Essentra® and Sensoril®. Dr. Abedon is an employee of NutraGenesis LLC, which sells Withania somnifera extract exclusively under the trade names Essentra® and Sensoril®. Dr. Ghosal was an unpaid adviser to Natreon Inc. at the time the study was conducted."

Effects Of An Aqueous Extract Of Withania Somnifera On Strength Training Adaptations And Recovery: The STAR Trial

Effect None
Values (mg/dl). Placebo: before 107.1 ± 34.3, after 113.2 ± 36.6. Ashwagandha: before 89.4 ± 30.5, after 87.8 ± 25.3
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 40
Gender Male
Age Range 18-29, 30-44, 45-64
Body Types Obese, Overweight, Average
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 40 healthy young, recreationally active men were allocated to take 500 mg of a potent ashwagandha extract (standardized to 10% withanolides) or placebo for 12 weeks.

The primary outcome was the change in muscle strength as measured by one-repetition maximum with the Smith machine bench press and back squat. There was a statistically significant increase in 1-repetition max for both squat and bench press. While the ashwagandha group saw a greater improvement in 7.5 km running down, this wasn't statistically significant between groups and the same was the case for average and peak power for squats and bench press, and number of repetitions.

There were no statistically significant changes between groups for body fat percentage, lean mass, fat mass, Android/Gynoid Ratio, visceral fat, or body mass. There were no statistically significant differences between groups on subjective assessments on a visual analog scale for perceived recovery, invigoration, mood, desire to work out, willingness to train, optimism, or soreness.

For blood testing, a large number of things were measured but none of it is particularly noteworthy (available in the values box in each respective outcome).
Funding issues for this study:
"Funding for this study was provided by Natreon, Inc. (New Brunswick, NJ, USA) through a restricted grant. The sponsor of the study was not involved in the conduct, interpretation, or the preparation of the final manuscript. A blinded third-party audited the collected data for accuracy and performed the statistical analyses."